Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor.

@article{Guo2007SorafenibIT,
  title={Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor.},
  author={Tianhua Guo and Narasimhan P. Agaram and Grace K C Wong and Glory Hom and David R. D'Adamo and Robert G Maki and Gary K. Schwartz and Darren R Veach and Bayard D. Clarkson and Samuel Singer and Ronald P. DeMatteo and Peter Besmer and Cristina R Antonescu},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2007},
  volume={13 16},
  pages={
          4874-81
        }
}
PURPOSE Resistance is commonly acquired in patients with metastatic gastrointestinal stromal tumor who are treated with imatinib mesylate, often due to the development of secondary mutations in the KIT kinase domain. We sought to investigate the efficacy of second-line tyrosine kinase inhibitors, such as sorafenib, dasatinib, and nilotinib, against the commonly observed imatinib-resistant KIT mutations (KIT(V654A), KIT(T670I), KIT(D820Y), and KIT(N822K)) expressed in the Ba/F3 cellular system… CONTINUE READING